The New Money
Posts
Smart Glasses Infiltrate Public Markets, Chamath's AI Bet, And Longevity Drug Breakthroughs From Dogs

Smart Glasses Infiltrate Public Markets, Chamath's AI Bet, And Longevity Drug Breakthroughs From Dogs

Uncovering the world’s most exciting early stage companies. Discover what’s next.

October 01, 2024

The Pursuit Of Smart Glasses Is Hitting The Public Markets

Multiple publicly traded companies have been ramping up the development of smart glasses technology. Artificial intelligence and augmented reality have continued to increase the underlying capabilities of smart glasses, leading companies such as Meta Platforms (NASDAQ: META), Vuzix (NASDAQ: VUZI), KITS Eyecare (TSX: KITS), and Innovation Eyewear (NASDAQ: LUCY) to make a flurry of new product launches and investments.

Chamath Palihapitiya Is Backing This Early Stage Public AI Company

Perimeter Medical Imaging AI (TSXV: PINK) has raised $9.8 million in a new financing round, which was led by Chamath Palihapitiya's family office Social Capital. The company has developed leading edge technology for breast cancer surgery that has been cleared by the United States Food and Drug Administration to provide real time visualization of excised tissue at the cellular level.

Could The Next Major Breakthrough In Human Longevity Drugs Start With Dogs?

Telomir Pharmaceuticals (NASDAQ: TELO) has been making potential breakthroughs in developing new therapeutics for human longevity through the pre-clinical advancement of their novel drug Telomir-1. The company previously saw potential validation when dosing two different dogs with pre-existing health challenges, with one dog showing remission from terminal cancer and the other regaining full mobility after suffering from severe arthritis.

The Sprint

Rocket Lab (NASDAQ: RKLB) completed testing and integration of its Pioneer spacecraft to be used by in-space pharmaceutical processing company Varda Space on their second ever mission.
Zefiro Methane (CBOE: ZEFI) has announced $32.8 million in annual revenue, which is their highest total revenue ever since inception.
Cerebras has filed to formally register for an IPO on the Nasdaq Global Market. The company recently launched the fastest inference technology in the world for artificial intelligence workloads.
PureTech Health (NASDAQ: PRTC) received official approval from the United States Food and Drug Administration for their novel therapeutic KarXT for the treatment of schizophrenia in adults.
Blink Charging (NASDAQ: BLNK) has successfully surpassed 100,000 electric vehicle chargers sold or deployed globally.
Generative artificial intelligence marketplace Arcade AI raised $17 million in a venture capital funding round led by Reid Hoffman and Ashton Kutcher.
DeFi Technologies (CBOE: DEFI) has launched a new Ethereum Exchange Traded Product onto the London Stock Exchange.

Looking to connect? Reach out and get in touch.

New here? Join our community of 25,000+ individuals interested in uncovering the world’s most exciting early stage companies.

Disclaimer: The New Money provides background information on early stage companies from publicly available sources. The New Money provides no advice on dealing in securities, is not a financial adviser and does not pretend to be so. This message is meant for information and educational purposes only. The information contained in this email is not to be considered factual or complete. Anybody interested in obtaining financial and other information on companies mentioned is advised to get it direct from the companies, or from their own investment adviser. The New Money does not intend for this information to be used to inform an investment decision. The New Money has been compensated by some of the companies mentioned in this email for awareness campaigns, which affects our ability to be unbiased. The Principals of The New Money may buy or sell shares of the mentioned companies without further notice. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities. The New Money and its principals and agents are not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Always do your own research and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment. Investing is inherently risky. While a potential for rewards exists, by investing, you are putting yourself at risk. You must be aware of the risks and be willing to accept them in order to invest in any type of security. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy or Sell securities. No representation is being made that any stock trade will or is likely to achieve profits. Comparisons made to other featured companies or past performance is not indicative of future results.